DE2319834A1 - Pyrazinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen - Google Patents
Pyrazinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungenInfo
- Publication number
- DE2319834A1 DE2319834A1 DE2319834A DE2319834A DE2319834A1 DE 2319834 A1 DE2319834 A1 DE 2319834A1 DE 2319834 A DE2319834 A DE 2319834A DE 2319834 A DE2319834 A DE 2319834A DE 2319834 A1 DE2319834 A1 DE 2319834A1
- Authority
- DE
- Germany
- Prior art keywords
- general formula
- oxide
- carboxy
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 17
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
- 230000008569 process Effects 0.000 title claims description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical class C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 44
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 150000003216 pyrazines Chemical class 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- RBYJWCRKFLGNDB-UHFFFAOYSA-N 5-methylpyrazine-2-carboxylic acid Chemical compound CC1=CN=C(C(O)=O)C=N1 RBYJWCRKFLGNDB-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 150000002169 ethanolamines Chemical class 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- OXQOBQJCDNLAPO-UHFFFAOYSA-N 2,3-Dimethylpyrazine Chemical compound CC1=NC=CN=C1C OXQOBQJCDNLAPO-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- -1 p-methoxybenzyl Chemical group 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BTYKRSQVJNDFFF-UHFFFAOYSA-N 5-methyl-4-oxidopyrazin-4-ium-2-carboxamide Chemical compound CC1=CN=C(C(N)=O)C=[N+]1[O-] BTYKRSQVJNDFFF-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- QYANNJBVADZUDN-UHFFFAOYSA-N (5-methylpyrazin-2-yl)methanol Chemical compound CC1=CN=C(CO)C=N1 QYANNJBVADZUDN-UHFFFAOYSA-N 0.000 description 1
- DZKRDHLYQRTDBU-UPHRSURJSA-N (z)-but-2-enediperoxoic acid Chemical compound OOC(=O)\C=C/C(=O)OO DZKRDHLYQRTDBU-UPHRSURJSA-N 0.000 description 1
- GIGRWGTZFONRKA-UHFFFAOYSA-N 1-(bromomethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CBr)C=C1 GIGRWGTZFONRKA-UHFFFAOYSA-N 0.000 description 1
- LQOMCBZFZAESLB-UHFFFAOYSA-N 2,3-dimethyl-1-oxidopyrazin-1-ium Chemical compound CC1=NC=C[N+]([O-])=C1C LQOMCBZFZAESLB-UHFFFAOYSA-N 0.000 description 1
- LYVNPPFWRNTXQE-UHFFFAOYSA-N 2-methyl-1-oxidopyrazin-1-ium Chemical compound CC1=CN=CC=[N+]1[O-] LYVNPPFWRNTXQE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- MLURVXFBKAKBIV-UHFFFAOYSA-N 3-methyl-1-oxidopyrazin-1-ium Chemical compound CC1=C[N+]([O-])=CC=N1 MLURVXFBKAKBIV-UHFFFAOYSA-N 0.000 description 1
- INCHBVKIVHUWEG-UHFFFAOYSA-N 5,6-dimethyl-4-oxidopyrazin-4-ium-2-carboxamide Chemical compound CC1=NC(C(N)=O)=C[N+]([O-])=C1C INCHBVKIVHUWEG-UHFFFAOYSA-N 0.000 description 1
- OYBQCUZBVHFPBU-UHFFFAOYSA-N 5-methylpyrazine-2-carboxamide Chemical compound CC1=CN=C(C(N)=O)C=N1 OYBQCUZBVHFPBU-UHFFFAOYSA-N 0.000 description 1
- VEAMIQACXBDBGD-UHFFFAOYSA-N 6-methyl-1h-pyrazine-2,2-dicarboxylic acid Chemical compound CC1=CN=CC(C(O)=O)(C(O)=O)N1 VEAMIQACXBDBGD-UHFFFAOYSA-N 0.000 description 1
- OODLOWQIRCXDEN-UHFFFAOYSA-N 6-methyl-4-oxidopyrazin-4-ium-2-carboxamide Chemical compound CC1=C[N+]([O-])=CC(C(N)=O)=N1 OODLOWQIRCXDEN-UHFFFAOYSA-N 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- WJKALUFNQRXEHN-UHFFFAOYSA-N CC1=NC=CN=C1.[K] Chemical compound CC1=NC=CN=C1.[K] WJKALUFNQRXEHN-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036035 hypolipemia Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
R , R und R , die gleich oder voneinander verschieden sein können, jeweils ein Wasserstoff- oder Halogenatom oder eine C, ,--Alkyl- oder -Alkoxygruppe, wobei mindestens einer der
R eine Hydroxygruppe oder eine C1 r~Alkoxygruppe oder eine Gruppe der Formel — I^R R , worin R-> und R , die gleich oder voneinander verschieden sein können, jeweils ein Wasserstoffatom oder eine C. ,«Alkyl gruppe bedeuten, sowie die pharmazeutisch verträglichen Salze dieser Verbin-·
düngen, wenn R eine Hydroxygruppe bedeutet.
in der R eine Hydroxygruppe bedeutet, in eine Verbindung der
der allgemeinen Formel I^ in der R eine Alkoxygruppe oder
in der R eine Alkoxygruppe bedeutet, kann in eine Verbindung
mel I, in der R eine -NR R -Gruppe bedeutet, in der einer der
in der R eine -NR R -Gruppe bedeutet, in der einer der Reste
II, worin R eine -MR -Gruppe bedeutet, können nach üblichen
meinen Formel II, worin R eine Hydroxy«* oder Alkoxygruppe bedeutet, beispielsweise durch Umsetzung einer Verbindung der allgemeinen Formel
stellt werden.
der R eine Hydroxygruppe bedeutet, in eine Verbindung der
der R eine Alkoxygruppe bedeutet, in eine Verbindung der all-
einer der Reste R und R oder beide Uasserstoffatome sind,
Claims (17)
- Patentansprüchein der bedeuten:12 3R , R und R , die gleich oder voneinander verschieden sein können, jeweils ein Wasserstoff- oder Halogenatom oder eine C, ,--Alkyl oder- -Alkoxygruppe, wobei mindestens einer der12 3
Reste R , R" und R kein Wasserstoffatom bedeutet,4
R eine Hydroxygruppe oder eine C1 r-Alkoxygruppe oder eineq r J-"" CLGruppe der Formel -MR R , worin R^ und R , die gleich oder voneinander verschieden sein können, jeweils ein Wasserstoffatom oder eine C, ,.-Alkylgruppe bedeuten,sowie die pharmazeutisch verträglichen Salze dieser Verbindungen,4
wenn R eine Hydroxygruppe bedeutet. - 2. Pyrazinderivate nach Anspruch 1, dadurch gekennzeichnet, daß in1 2 der allgemeinen Formel I mindestens einer der Reste R , R undR eine Methylgruppe bedeutet und die anderen Reste Wasserstoffatome bedeuten.
- 3. Pyrazinderivate nach Anspruch 1 und/oder 2, dadurch gekennzeichnet, daß sie in Form eines Äthanolaminsalzes vorliegen.30 9846/1134
- 4» 2 ~ Ca rbamoy 1 ·· 5 -me thy 1ΐ>γ r a ζ in» k■«- ο xyd.
- 5. 2~Carbarnoyl-5,6-diraethylpyrazi'a»4-oxyd*
- 6. 2~Carbamoyl-6-methylpyrazin-4»oxyd,-
- 7. 2"(N,NrDiäthylcarbamoyl)
- 8. 2- (N-Ätlrylcarbamoyl)-S-me
- 9. 2-Carboxy-5"metliylxjyrazin~4-oxyd.
- 10. 2"Carboxy-6-methyipyrazi*n-4-o:-iyd.
- 11. 2**Carboxy~5,6-dimetliylpyrazin-^-oxyd.
- 12. 2-Carbox5''~5-rneth3'-lpyrazin-4"-ox)-däthanolö.rain-Salz.
- 13. 2-Carboxy-5,6-dimethylp3'-razin~4-o;iyd-ät1aanolainin~Salz.
- 14. 2-Carboxy-5-methylpyrazin~4~oxyd-äthylester,
- 15. Verfaliren zur Herstellung der Pyrazinderivate nach mindestens einem der vorhergehenden Ansprüche, dadurch gekennzeichnetf daß man eine Verbindung der allgemeinen Formel(H)COR309846/113412 3 4 -in der R , R ,R und R die in Anspruch 1 angegebenen Bedeutungen haben, oxydiert und anschließend gewünschtenfalls die dabei erhaltene Verbindung der allgemeinen Formel I nach an sich bekannten Methoden in eine andere Verbindung der allgemeinen For-4 tnel I überführt und gewünschtenfalls, wenn R eine Hydroxygruppe bedeutet, die Verbindung der allgemeinen Formel I mit einer Base umsetzt unter Bildung eines pharmazeutisch verträglichen Salzes.
- 16. Pyrazinderivat der in Anspruch 1 angegebenen allgemeinen Formel I, wie es nach dem Verfahren gemäß Anspruch 15 erhältlich ist.
- 17. Pharmazeutische Zubereitung, dadurch gekennzeichnet, daß sie mindestens ein Pyrazinderivat nach' den Ansprüchen 1 bis 14 und 16 sowie ein pharmazeutisch verträgliches Träger- oder Verdünnungsmaterial enthält.309846/1134
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2366372 | 1972-04-28 |
Publications (3)
Publication Number | Publication Date |
---|---|
DE2319834A1 true DE2319834A1 (de) | 1973-11-15 |
DE2319834B2 DE2319834B2 (de) | 1982-06-24 |
DE2319834C3 DE2319834C3 (de) | 1983-02-03 |
Family
ID=11208983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2319834A Expired DE2319834C3 (de) | 1972-04-28 | 1973-04-18 | Derivate von 2-Carboxy-pyrazin-4-oxiden, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen |
Country Status (21)
Country | Link |
---|---|
JP (1) | JPS5535384B2 (de) |
AT (1) | AT326669B (de) |
AU (1) | AU470007B2 (de) |
BE (1) | BE798752A (de) |
CA (1) | CA1000278A (de) |
CH (1) | CH582161A5 (de) |
CS (1) | CS172972B2 (de) |
DE (1) | DE2319834C3 (de) |
DK (1) | DK138796B (de) |
FI (1) | FI55033C (de) |
FR (1) | FR2183049B1 (de) |
GB (1) | GB1361967A (de) |
HK (1) | HK66876A (de) |
HU (1) | HU165674B (de) |
IL (1) | IL42026A (de) |
MY (1) | MY7700077A (de) |
NL (1) | NL178595C (de) |
NO (1) | NO137728C (de) |
SE (1) | SE387344B (de) |
SU (1) | SU578876A3 (de) |
ZA (1) | ZA732712B (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2910824A1 (de) * | 1978-03-23 | 1979-09-27 | Erba Farmitalia | 2-hydroxymethyl-pyrazin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische produkte |
EP0201934A2 (de) * | 1985-05-17 | 1986-11-20 | Montedison S.p.A. | Verfahren zur Herstellung von 2-Carboxypyrazin-4-oxiden |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8202105A (nl) * | 1981-05-28 | 1982-12-16 | Erba Farmitalia | Werkwijze voor het bereiden van pyrazinederivaten. |
CA1205075A (en) * | 1982-03-08 | 1986-05-27 | Claudio Santini | Preparation of pyrazine derivatives |
GB2133004B (en) * | 1982-11-04 | 1986-06-11 | Ici Plc | Process for the extraction of metal values and novel metal extractants |
US4962111A (en) * | 1989-06-08 | 1990-10-09 | The Research Foundation Of State University Of New York | Pyrazinoic acid esters as antituberculosis agents |
US5643912A (en) * | 1993-12-17 | 1997-07-01 | The Research Foundation Of State University Of Ny | Pyrazinoic acid esters as anti-mycobacterium avium agents |
CN113493421A (zh) * | 2020-04-08 | 2021-10-12 | 鲁南制药集团股份有限公司 | 一种1,2-二(4-吡啶基)乙烷-阿昔莫司共晶 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3452014A (en) * | 1964-08-14 | 1969-06-24 | Upjohn Co | 2,5-dimethylpyrazine p-toluenesulfonate |
AT291264B (de) * | 1969-05-05 | 1971-07-12 | Daiichi Seiyaku Company Ltd | Verfahren zur Herstellung von neuen Pyrazincarbonsäurederivaten |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6907199A (en) * | 1969-05-09 | 1970-11-11 | Hypoglycaemic pyrazine derivs |
-
1973
- 1973-04-12 GB GB1764573A patent/GB1361967A/en not_active Expired
- 1973-04-12 AU AU54413/73A patent/AU470007B2/en not_active Expired
- 1973-04-13 IL IL42026A patent/IL42026A/en unknown
- 1973-04-18 DE DE2319834A patent/DE2319834C3/de not_active Expired
- 1973-04-18 AT AT345073A patent/AT326669B/de active Protection Beyond IP Right Term
- 1973-04-19 ZA ZA732712A patent/ZA732712B/xx unknown
- 1973-04-24 CS CS2929A patent/CS172972B2/cs unknown
- 1973-04-25 NO NO1705/73A patent/NO137728C/no unknown
- 1973-04-26 BE BE130442A patent/BE798752A/xx not_active IP Right Cessation
- 1973-04-26 JP JP4832373A patent/JPS5535384B2/ja not_active Expired
- 1973-04-26 NL NLAANVRAGE7305867,A patent/NL178595C/xx not_active IP Right Cessation
- 1973-04-26 FI FI1336/73A patent/FI55033C/fi active
- 1973-04-27 CA CA169,694A patent/CA1000278A/en not_active Expired
- 1973-04-27 SE SE7305965A patent/SE387344B/xx unknown
- 1973-04-27 CH CH605873A patent/CH582161A5/xx active Protection Beyond IP Right Term
- 1973-04-27 FR FR7315308A patent/FR2183049B1/fr not_active Expired
- 1973-04-27 DK DK232573AA patent/DK138796B/da not_active IP Right Cessation
- 1973-04-27 SU SU7301908970A patent/SU578876A3/ru active
- 1973-04-27 HU HUEA129A patent/HU165674B/hu unknown
-
1976
- 1976-10-28 HK HK668/76*UA patent/HK66876A/xx unknown
-
1977
- 1977-12-30 MY MY77/77A patent/MY7700077A/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3452014A (en) * | 1964-08-14 | 1969-06-24 | Upjohn Co | 2,5-dimethylpyrazine p-toluenesulfonate |
AT291264B (de) * | 1969-05-05 | 1971-07-12 | Daiichi Seiyaku Company Ltd | Verfahren zur Herstellung von neuen Pyrazincarbonsäurederivaten |
Non-Patent Citations (1)
Title |
---|
Helwig, Moderne Arzneimittel, 4. Auflage, 1972, S. 1035 ff und S. 1039 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2910824A1 (de) * | 1978-03-23 | 1979-09-27 | Erba Farmitalia | 2-hydroxymethyl-pyrazin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische produkte |
EP0201934A2 (de) * | 1985-05-17 | 1986-11-20 | Montedison S.p.A. | Verfahren zur Herstellung von 2-Carboxypyrazin-4-oxiden |
EP0201934A3 (en) * | 1985-05-17 | 1987-11-19 | Montedison S.P.A. | Process for the preparation of 2-carboxypyrazines 4-oxide |
Also Published As
Publication number | Publication date |
---|---|
FR2183049A1 (de) | 1973-12-14 |
CS172972B2 (de) | 1977-01-28 |
MY7700077A (en) | 1977-12-31 |
ATA345073A (de) | 1975-03-15 |
IL42026A0 (en) | 1973-06-29 |
DE2319834C3 (de) | 1983-02-03 |
HK66876A (en) | 1976-11-05 |
NO137728B (no) | 1978-01-02 |
CH582161A5 (de) | 1976-11-30 |
NL178595B (nl) | 1985-11-18 |
CA1000278A (en) | 1976-11-23 |
AU5441373A (en) | 1974-10-17 |
HU165674B (de) | 1974-10-28 |
GB1361967A (en) | 1974-07-30 |
AT326669B (de) | 1975-12-29 |
IL42026A (en) | 1976-07-30 |
FI55033C (fi) | 1979-05-10 |
NL178595C (nl) | 1986-04-16 |
DK138796B (da) | 1978-10-30 |
SU578876A3 (ru) | 1977-10-30 |
ZA732712B (en) | 1974-11-27 |
JPS5535384B2 (de) | 1980-09-12 |
AU470007B2 (en) | 1976-02-26 |
NO137728C (no) | 1978-04-12 |
NL7305867A (de) | 1973-10-30 |
JPS4954386A (de) | 1974-05-27 |
BE798752A (fr) | 1973-08-16 |
DK138796C (de) | 1979-04-30 |
DE2319834B2 (de) | 1982-06-24 |
SE387344B (sv) | 1976-09-06 |
FI55033B (fi) | 1979-01-31 |
FR2183049B1 (de) | 1975-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1445154C3 (de) | 1,4-Dihydro-1,8-naphthyridinderi vate und ein Verfahren zu ihrer Herstellung | |
DE2706977A1 (de) | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung | |
DE2315801A1 (de) | 2-alkyl-3-acyl-pyrazolo-eckige klammer auf 1,5-a eckige klammer zu-pyridine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate | |
DE2635853A1 (de) | Pyrrolidin-2-on-derivate, verfahren zu ihrer herstellung und sie enthaltendes arzneimittel | |
DE2164058B2 (de) | Basisch substituierte Benzylphthalazinon-Derivate, ihre Salze, Verfahren zu ihrer Herstellung und diese Produkte enthaltende pharmazeutische Präparate | |
DE2319834A1 (de) | Pyrazinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen | |
DE2253750C3 (de) | Apovincaminsaure-alkylester, Verfahren zu ihrer Herstellung und pharmazeutische | |
DE2941288C2 (de) | ||
DE2359076C2 (de) | 2β,16β-Dipiperidino-5α-androstane und Verfahren zu ihrer Herstellung | |
DE2726820A1 (de) | Imidazothiazine | |
DE3150005A1 (de) | Verfahren zur herstellung von chinolinsaeure | |
DE2446100B2 (de) | Phenoxyalkancarbonsäureamide von Thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und Arzneimittel | |
CH440292A (de) | Verfahren zur Herstellung neuer Aminopyrazole | |
DE1493513C3 (de) | Sulfamylanthranilsäuren, deren therapeutisch verwendbare Salze, Verfahren zu ihrer Herstellung und diese enthaltenden pharmazeutischen Präparate | |
DE1242619B (de) | Verfahren zur Herstellung von neuen Nikotionsaeureestern | |
DE1670539C3 (de) | Diacylthiamine und Verfahren zu deren Herstellung | |
DE2131153A1 (de) | Wasserloesliche antibakterielle Verbindungen unterirdischer Stollen | |
DE1493524A1 (de) | Aminosaeuren | |
AT390615B (de) | Verfahren zur herstellung von neuen, 3-substituierten 2-oxo-hexahydro-pyrimido (1,2-a)azepinen sowie von deren pharmazeutisch geeigneten salzen | |
EP0054672A1 (de) | Lactamverbindungen, diese enthaltende Arzneimittel und Verfahren zur Herstellung dieser Verbindungen und Arzneimittel | |
DE2549863C3 (de) | Pyridoxyliden-p-amino-benzoesäurederivate, deren Herstellung und Verwendung | |
DE2334973A1 (de) | Neue biphenyl-derivate | |
DE1224738B (de) | Verfahren zur Herstellung von Cholestan-3, 5, 6-triol-3-estern oder -3, 6-diestern soowie von deren Salzen | |
DE2404924A1 (de) | Ergolinderivate | |
DE1493567C3 (de) | Ester von alpha-Alkylthyroxinderivaten und Verfahren zu ihrer Herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8136 | Disposal/non-payment of the fee for publication/grant | ||
8180 | Miscellaneous part 1 |
Free format text: WIEDEREINSETZUNG IN DEN VORHERGEHENDEN STAND |
|
8227 | New person/name/address of the applicant |
Free format text: FARMITALIA CARLO ERBA S.P.A., 20159 MILANO, IT |
|
8226 | Change of the secondary classification |
Ipc: A61K 31/495 |
|
C3 | Grant after two publication steps (3rd publication) | ||
8328 | Change in the person/name/address of the agent |
Free format text: REDIES, B., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 4000 DUESSELDORF |
|
8327 | Change in the person/name/address of the patent owner |
Owner name: FARMITALIA CARLO ERBA S.R.L., MAILAND/MILANO, IT |
|
8328 | Change in the person/name/address of the agent |
Free format text: COHAUSZ, W., DIPL.-ING. KNAUF, R., DIPL.-ING. COHAUSZ, H., DIPL.-ING., 4000 DUESSELDORF WERNER, D.,DIPL.-ING. DR.-ING., 4150 KREFELD REDIES, B., DIPL.-CHEM. DR.RER.NAT. FITZNER, U., DIPL.-ING. DR.-ING. DR.JUR., PAT.-ANWAELTE, 4000 DUESSELDORF |
|
8328 | Change in the person/name/address of the agent |
Free format text: EITLE, W., DIPL.-ING. HOFFMANN, K., DIPL.-ING. DR.RER.NAT. LEHN, W., DIPL.-ING. FUECHSLE, K., DIPL.-ING. HANSEN, B., DIPL.-CHEM. DR.RER.NAT. BRAUNS, H., DIPL.-CHEM. DR.RER.NAT. GOERG, K., DIPL.-ING. KOHLMANN, K., DIPL.-ING. KOLB, H., DIPL.-CHEM. DR.RER.NAT. RITTER UND EDLER VON FISCHERN, B., DIPL.-ING., PAT.-ANWAELTE NETTE, A., RECHTSANW., 8000 MUENCHEN |